DexCom (NASDAQ:DXCM) Insider Kevin Sayer Sells 26,756 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the transaction, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

DexCom stock traded up $2.38 during trading hours on Tuesday, hitting $75.75. 1,200,643 shares of the stock traded hands, compared to its average volume of 5,187,351. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm’s 50 day moving average price is $72.63 and its 200-day moving average price is $68.97. The stock has a market capitalization of $29.23 billion, a price-to-earnings ratio of 32.31, a P/E/G ratio of 1.18 and a beta of 1.45. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business posted $0.32 earnings per share. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, equities analysts expect that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Reflection Asset Management acquired a new stake in shares of DexCom during the 4th quarter valued at about $25,000. Ascentis Independent Advisors purchased a new position in DexCom during the first quarter worth approximately $25,000. MCF Advisors LLC purchased a new position in DexCom during the fourth quarter worth approximately $32,000. ORG Partners LLC increased its position in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares in the last quarter. Finally, Wellington Grp LLC raised its stake in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on DXCM. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Truist Financial boosted their target price on shares of DexCom from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. UBS Group set a $96.00 price target on DexCom in a research report on Tuesday. Finally, Barclays reissued an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $85.40.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.